ADIL net incomeQ2 2026-$51.99M
ADIL net income was -$51.99M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.96M a year earlier. For the full fiscal 2025 it was -$7.98M, compared with -$13.20M in fiscal 2024.
Adial Pharmaceuticals Inc (ADIL) financials
For the twelve months ended Jun 30, 2026, Adial Pharmaceuticals Inc reported -$57.80M of net income.
- Net income, TTM
- -$57.80M
- Cash
- $28.71M
- Market cap
- $10.5M
FY2017FY2025
ADIL revenue and earnings growth
ADIL EPSQ2 2026-$11.25
ADIL diluted EPS was -$11.25 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$11.93.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.62M | $3.23M | $1.27M | $1.95M | $8.40M | $5.85M | $3.97M | $368.5K | $182.1K |
| Selling, general and admin | $5.18M | $5.06M | $5.62M | $8.91M | $9.34M | $5.07M | $4.28M | $6.62M | $813.2K |
| Operating income | -$7.80M | -$8.28M | -$6.89M | -$10.86M | -$19.29M | -$10.93M | -$8.24M | -$6.99M | -$995.3K |
| Pre-tax income | -$7.98M | -$13.20M | -$7.00M | -$10.80M | -$19.52M | -$10.89M | -$8.59M | -$11.63M | -$1.14M |
| Income tax | - | - | - | -$502 | -$94.1K | - | - | - | - |
| Net income | -$7.98M | -$13.20M | -$5.12M | -$12.73M | -$19.42M | -$10.89M | -$8.59M | -$11.63M | -$1.14M |
| EPS, basic | -$11.93 | -$68.01 | -$90.00 | -$317.75 | -$650.00 | -$543.75 | -$543.75 | -$1525.00 | -$218.75 |
| EPS, diluted | -$11.93 | -$68.01 | -$90.00 | -$317.75 | -$650.00 | -$543.75 | -$543.75 | -$1525.00 | -$218.75 |
| Diluted shares | 668,630 | 194,059 | 56,986.44 | 40,060.2 | 29,741.997 | 19,941.003 | 15,763.978 | 7,614.981 | 278.851 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.88M | $3.75M | $2.83M | $4.00M | $6.06M | $4.40M | $6.78M | $3.87M | $18.2K |
| Current assets | $6.18M | $4.06M | $3.20M | $4.78M | $6.46M | $5.14M | $7.67M | $4.69M | $27.2K |
| Goodwill | - | - | - | $249.0K | $249.0K | - | - | - | - |
| Total assets | $6.67M | $5.04M | $4.74M | $5.73M | $7.47M | $5.49M | $7.68M | $4.70M | $34.5K |
| Current liabilities | $1.40M | $975.9K | $653.1K | $1.79M | $2.72M | $1.51M | $539.1K | $258.0K | $1.03M |
| Total liabilities | $1.40M | $975.9K | $653.1K | $2.46M | $3.97M | $1.51M | - | - | - |
| Shareholders' equity | $5.28M | $4.07M | $4.08M | $3.28M | $3.51M | $3.99M | $7.14M | $4.44M | -$997.6K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.49M | -$6.92M | -$6.81M | -$11.19M | -$11.95M | -$7.63M | -$6.34M | -$2.50M | -$494.9K |
| Capital expenditures | - | - | - | - | $64.6K | - | - | - | - |
| Free cash flow | - | - | - | - | -$12.01M | - | - | - | - |
| Investing cash flow | $150.0K | - | $1.50M | - | -$34.0K | -$350.0K | - | - | $35.1K |
| Financing cash flow | $8.47M | $7.85M | $4.13M | $9.13M | $13.64M | $5.61M | $9.25M | $6.35M | $390.0K |
| Share repurchases | - | - | $1.7K | - | - | - | - | - | - |
| Stock-based compensation | $676.2K | $796.8K | $1.75M | $3.37M | $4.24M | $2.01M | $1.60M | $5.37M | $205.4K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -151.2% | -324.4% | -125.5% | -388.6% | -553.7% | -273.3% | -120.3% | -261.9% | - |
| Return on assets | -119.5% | -261.6% | -108.2% | -222.1% | -259.8% | -198.4% | -111.9% | -247.5% | -3298.4% |
| Current ratio | 4.42 | 4.16 | 4.90 | 2.67 | 2.37 | 3.41 | 14.24 | 18.19 | 0.03 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $440.0K | $432.5K | $619.4K | $521.1K | $732.0K | $746.9K | $730.8K | $1.03M | $1.01M | $454.3K | $264.4K | $207.1K |
| Selling, general and admin | $5.40M | $1.57M | $1.27M | $1.24M | $1.15M | $1.52M | $1.21M | $1.18M | $1.27M | $1.39M | $1.52M | $1.15M |
| Operating income | -$52.02M | -$2.00M | -$1.89M | -$1.76M | -$1.88M | -$2.27M | -$1.94M | -$2.21M | -$2.29M | -$1.85M | -$1.78M | -$1.36M |
| Pre-tax income | - | - | - | - | - | - | -$2.07M | -$2.19M | -$2.46M | -$6.48M | -$1.90M | -$1.35M |
| Net income | -$51.99M | -$2.02M | -$2.00M | -$1.79M | -$1.96M | -$2.23M | -$2.07M | -$2.19M | -$2.46M | -$6.48M | -$1.92M | -$1.38M |
| EPS, basic | -$11.25 | -$1.48 | - | -$2.00 | -$4.61 | -$8.52 | - | -$9.50 | -$14.75 | -$54.75 | - | -$29.50 |
| EPS, diluted | -$11.25 | -$1.48 | - | -$2.00 | -$4.61 | -$8.52 | - | -$9.50 | -$14.75 | -$54.75 | - | -$29.50 |
| Diluted shares | 4.6M | 1.4M | - | 886,852.36 | 424,908 | 261,590 | - | 233,427.28 | 167,310.4 | 118,156.52 | - | 47,141.48 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $28.71M | $4.58M | $5.88M | $4.61M | $5.92M | $2.37M | $3.75M | $5.20M | $3.29M | $5.03M | $2.83M | $315.9K |
| Current assets | $28.84M | $4.80M | $6.18M | $5.01M | $6.08M | $2.63M | $4.06M | $5.62M | $3.82M | - | $3.20M | $1.14M |
| Total assets | $29.09M | $5.23M | $6.67M | $5.66M | $6.80M | $3.45M | $5.04M | $6.71M | $4.95M | - | $4.74M | $2.87M |
| Current liabilities | $5.12M | $1.51M | $1.40M | $1.15M | $1.21M | $1.32M | $975.9K | $829.0K | $671.9K | - | $653.1K | $528.2K |
| Total liabilities | $28.93M | $1.51M | $1.40M | $1.15M | $1.21M | $1.32M | $975.9K | $829.0K | $671.9K | - | $653.1K | $528.2K |
| Shareholders' equity | -$38.38M | $3.72M | $5.28M | $4.51M | $5.59M | $2.13M | $4.07M | $5.88M | $4.28M | $6.12M | $4.08M | $2.34M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.36M | -$1.61M | -$1.32M | -$1.83M | -$1.75M | -$1.59M | -$1.45M | -$1.69M | -$2.15M | -$1.63M | -$1.22M | -$1.39M |
| Investing cash flow | - | - | $0 | $0 | $0 | $150.0K | - | - | - | - | $350.0K | $350.0K |
| Financing cash flow | $25.21M | $315.3K | $2.60M | $524.8K | $5.30M | $50.6K | $0 | $3.61M | $411.1K | $3.82M | $3.38M | $138.7K |
| Share repurchases | - | - | - | - | - | - | - | - | - | - | $0 | - |
| Stock-based compensation | $137.1K | $147.9K | $168.0K | $147.2K | $124.3K | $236.7K | $180.2K | $188.3K | $202.4K | $226.0K | $280.8K | $268.4K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.63 | 3.18 | 4.42 | 4.34 | 5.02 | 1.99 | 4.16 | 6.78 | 5.69 | - | 4.90 | 2.15 |
Source: XBRL data Adial Pharmaceuticals Inc files with the SEC, latest filing dated Oct 21, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Aug 21, 2023; 1-for-25, first reported Mar 5, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ADIL peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ADIL | - | - | -$57.80M | - | $10.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
ADIL FAQ
4 questionsIs ADIL profitable?
No. Adial Pharmaceuticals Inc reported a net loss of $57.80M for the twelve months ended Jun 30, 2026.How much cash and debt does ADIL have?
Adial Pharmaceuticals Inc reported $28.71M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did ADIL last report financial results?
The latest statements here come from Adial Pharmaceuticals Inc's 10-Q/A filed on Oct 21, 2026, covering the period ended Jun 30, 2026.Where does this ADIL financial data come from?
Quantisnow builds these statements from the structured XBRL data Adial Pharmaceuticals Inc files with the SEC. It is provided for information only and is not investment advice.